Revised Procedures for CDR and pCODR For all drug applications filed for review through either the Common Drug Review (CDR) or pan-Canadian Oncology Drug Review (pCODR) process on or after April 1, 2016, CADTH will no longer accept confidential submitted prices. The submitted price will be disclosed in all applicable CDR ... Read More


In November 2015, CADTH received stakeholder feedback on proposed changes to the pan-Canadian Oncology Drug Review (pCODR) program that would allow for broader clinician participation in the pCODR process. Feedback was received from three clinicians, three patient advocacy groups, three pharmaceutical companies, and two industry association groups. This stakeholder feedback ... Read More


Based on stakeholder feedback received in May 2015, CADTH has announced that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately. Please note that for ... Read More


CADTH has posted its Guidelines for Manufacturers on Application Fees for the CADTH pan-Canadian Oncology Drug Review on its website, after stakeholder comments and feedback were received last month. Key changes made in response to stakeholders’ comments are detailed in CADTH’s April 1, 2015 notice of implementation. For ... Read More


Effective April 1, 2015, the pCODR office will be moving to 154 University Avenue, Suite 300, Toronto from its current location at 1 University Ave, Suite 300. This move is to facilitate pCODR’s transition to CADTH while maintaining its central location in downtown Toronto. Please note the new main telephone and fax ... Read More


CADTH will be implementing an application fee for manufacturer applications filed with the pan-Canadian Oncology Drug Review (pCODR). The proposed fee will apply to all manufacturer applications with a Health Canada Notice of Compliance (NOC) or Notice of Compliance with Conditions (NOC/c) date of April 1, 2015 or later. The ... Read More


Following the transfer of the pan-Canadian Oncology Drug Review (pCODR) to CADTH beginning in April 2014, a survey was conducted to identify stakeholder concerns regarding the transfer. Stakeholder Information Sessions on the transfer held on June 9, 2014 were attended by patient advocacy groups, oncology professionals, pharmaceutical manufacturers, associations, and consultants. ... Read More


On February 11, 2014, the pan-Canadian Oncology Drug Review (pCODR) invited stakeholder comments on proposed changes to the pCODR Procedures and related guidance documents.A summary of the stakeholder feedback can be found here.  In view of the stakeholder comments, effective June 1, 2014, pCODR will no longer ... Read More


The Federal / Provincial / Territorial Deputy Ministers of Health recently announced the transfer of the pan-Canadian Oncology Drug Review (pCODR) to the Canadian Agency for Drugs and Technologies in Health (CADTH) effective April 1, 2014. This decision was made to further consolidate policy direction across different drug ... Read More